11 results about "Hashimoto thyroiditis" patented technology

The invention discloses a combined medicine composition of a thyroid Qixia patch and a selenium yeast tablet and application of the combined medicine composition, and belongs to the technical field of medicines. The composition is composed of a thyroid and astragalus mongholicus summer patch and a selenium yeast tablet, the thyroid and astragalus mongholicus summer patch is prepared by grinding astragalus mongholicus, selfheal, radix clematidis, turmeric, airpotato yam and semen brassicae as raw materials, and adding vaseline to prepare paste. The selenium yeast tablet is used for oral administration and is matched with the thyroid qi-summer patch for external application on the neck, and the treatment course is 3 months. Clinical verifications show that the total effective rate of the composition reaches 87.80%, the composition can effectively improve symptoms such as anterior cervical mass, dysphoria, irritability and the like, reduce the level of serum TPOAb, reduce thyroid and nodule volumes and improve nodule blood flow, the safety is good, the curative effect is superior to that of pure western medicine treatment, and an effective treatment scheme is provided for related diseases.

A traditional Chinese medicine composition for treating Hashimoto's thyroiditis comprises the following raw materials in the indicated weight ratios: 50-200 parts Rehmannia glutinosa (processed), 10-60 parts Cinnamomum cassia, 30-100 parts Ephedra sinica, 10-60 parts Cervi cornu slices, 10-60 parts Zingiber officinale (dried), 30-80 parts Glycyrrhiza uralensis (processed), 50-200 parts Paeonia lactiflora (white), 50-200 parts Paeonia veitchii (red), 30-100 parts Paeonia suffruticosa (moutan bark), 50-200 parts Codonopsis pilosula, 50-200 parts Angelica sinensis, 50-200 parts Prunus persica, and 30-100 parts Carthamus tinctorius. The preparation method is as follows: Place Rehmannia glutinosa, Cinnamomum cassia, Ephedra sinica, deer antler slices, dried ginger, prepared licorice root, white peony root, red peony root, peony bark, Codonopsis pilosula, Angelica sinensis, peach kernel, and safflower in a container, add 8 times the total weight of the herbs in cold water, soak for 30 minutes to fully moisten the herbs, bring to a boil over high heat, then simmer over low heat for another 30 minutes; for the second decoction, filter out the liquid from the first decoction, add the remaining herbs and 6 times the total weight of the herbs in warm water, just enough to cover the herbs; soak for 30 minutes, bring to a boil over high heat, then simmer over low heat for another 20 minutes; after the decoction is completed, combine the two decoctions, filter out the dregs, and obtain the traditional Chinese medicine decoction.

This invention provides a traditional Chinese medicine preparation for treating Hashimoto's thyroiditis and its preparation method, belonging to the field of traditional Chinese medicine pharmaceutical technology. The preparation is made from Curcuma zedoaria, oyster shell, Eclipta prostrata, Ligustrum lucidum, Sargassum, processed Aconitum carmichaelii, Cremastra appendiculata, Duchesnea indica, Hedyotis diffusa, Artemisia capillaris, Oroxylum indicum, and cinnamon. The formula is meticulously formulated, closely addressing the core pathogenesis of Hashimoto's thyroiditis: "phlegm and blood stasis, spleen and kidney deficiency, and nutritional imbalance." It focuses on "eliminating masses and dispersing nodules, promoting qi and blood circulation," fully embodying the TCM diagnostic and treatment approach of "differentiating syndromes and treating accordingly, addressing both the root cause and symptoms." This invention's preparation has a good therapeutic effect on Hashimoto's thyroiditis, effectively improving thyroid autoimmune disorders, regulating thyroid function, and alleviating symptoms of local thyroid inflammation in experimentally induced Hashimoto's thyroiditis rats. Further clinical observation studies have found that this preparation significantly improves the overall effective rate of clinical treatment for Hashimoto's thyroiditis patients, providing a new approach to the treatment of this condition.

The application provides a traditional Chinese medicine compound for treating Hashimoto's thyroiditis, and relates to the technical field of traditional Chinese medicine pharmacy.The traditional Chinese medicine compound is composed of traditional Chinese medicinal materials of mountain yam, Humulus scandens, catechu, Sabina tibetica, bitter ground ivy, crossandra infundibuliformis, Usnea, luffa, bergamot, oleander, rootless incense, gardenia leaf, eucommia, mulberry ear, has the effects of resolving phlegm and removing nodules, promoting blood circulation to remove stasis, regulating qi to relieve depression, and clearing heat and resolving toxins, is suitable for treating Hashimoto's thyroiditis.The traditional Chinese medicine compound can effectively regulate the levels of TPOAb, TgAb and thyroid hormone, and has a good anti-inflammatory effect, so that excellent treatment of Hashimoto's thyroiditis is realized.The traditional Chinese medicine compound can be further popularized and applied as a medicine for treating Hashimoto's thyroiditis.

The idea of the patent includes a new principle, which is the detection of immune complexes using ELISA technology, which is a new and modern principle that is added to the four principles of ELISA, the new principle (the fifth ELISA) depends on detection of immune complexes, which consist of two different parts of proteins (an antigen - an antigen). This complex can be detected through this new principle, and it was applied to the immune complex (thyroid-stimulating hormone receptors and antibodies formed against it) Hashimoto's patients. It was considered an example of applying this theory, the immune complex was actually detected, its concentration determined, and compared to other techniques. A standard solution specially designed for this purpose was used to prove this theory. In this patent, a new kit is specifically designed to detect these immune complexes. Immune complex, the group is considered successful. In terms of use.

The present disclosure relates to sequence selective deoxyribonucleic acid (DNA) binding compounds comprising a polyamide moiety configured to bind a DNA sequence. The invention also relates pharmaceutical compositions comprising the compounds, and methods of using the compounds for restoring expression of autoimmune regulator (AIRE) gene. The invention further relates to pharmaceutical compositions comprising the compounds, and methods of using the compounds for and treating an autoimmune disease (e.g., Addison disease, Celiac disease, dermatomyositis. Graves disease, Hashimoto thyroiditis, inflammatory bowel disease, multiple sclerosis (MS), myasthenia gravis, pernicious anemia, reactive arthritis, Sjogren syndrome, systemic lupus erythematosus, and type I diabetes). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention relates to the field of medical information processing and chronic disease risk assessment technology, specifically a Hashimoto's thyroiditis risk assessment and prediction system and method applicable to different scenarios. It includes: S1. Dataset construction; S2. Variable selection; S3. Construction of a three-layer prediction model; S4. Comparison and optimization of machine learning algorithms; S5. Construction of a simplified scoring model; and S6. Development and deployment of a visual web-based assessment tool. This invention features representative real-world data, adapts to different resource configurations, constructs a multi-dimensional prediction system, significantly lowers the application threshold, improves model interpretability and clinical feasibility, and achieves an integrated assessment process of input indicators → output risk level → provision of intervention suggestions, supporting its application in primary healthcare institutions.

The application discloses a Hashimoto's thyroiditis model, a construction method thereof and an antigen, and the construction method comprises the following steps: preparing a pig thyroid lyophilized powder; selecting 8-week-old EAT susceptible strain CBA / J female mice, and injecting phosphate buffered saline solutions containing the pig thyroid lyophilized powder at the 0th day, the 7th day and the 14th day after 8 weeks; injecting phosphate buffered saline solutions containing lipopolysaccharide at a predetermined time interval; when the EAT susceptible strain CBA / J female mice are 12 weeks old, the modeling effect is measured from thyroid pathological morphology and EAT scores, serum TgAb concentration, serum TPOAb concentration and the number of each T lymphocyte subpopulation in the spleen. After the mice are continuously injected with the phosphate buffered saline solutions containing the pig thyroid lyophilized powder and the lipopolysaccharide for three times through the tail vein, the mice produce autoantibodies, and obvious lymphatic infiltration appears in the thyroid tissue, which indicates that the pig thyroid lyophilized powder can induce the occurrence of Hashimoto's thyroiditis, and a new thought is provided for the pathogenesis of Hashimoto's thyroiditis.

The invention provides a traditional Chinese medicine compound preparation for auxiliary nursing of hashimoto thyroiditis, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine compound preparation is prepared from the following traditional Chinese medicinal materials: resina liquidambaris, homalomena occulta, sword brake herb, walnut twig, resina erythrinae, siberian elm bark, polygonum cuspidatum, red-knees herb, perfoliote knotweed herb, akebia fruit, oroxylum indicum, semen brassicae, kadsura longipedunculata, rhizoma dioscoreae nipponicae, ginseng leaf and rhizoma zingiberis. According to the traditional Chinese medicine compound preparation, the autoantibody titers of HT model rat serum TPOAb and TgAb can be effectively reduced, thyroid function indexes FT3, FT4 and TSH are effectively improved, and meanwhile generation and activity of HT model serum inflammatory factors can be effectively inhibited. The traditional Chinese medicine compound preparation disclosed by the invention has a relatively good treatment effect in the aspects of inhibiting autoantibody generation and reducing thyroid damage and can be used for effectively treating hashimoto thyroiditis by inhibiting inflammatory response. The traditional Chinese medicine compound preparation disclosed by the invention is expected to be further developed and researched as a medicine for treating or assisting in treating hashimoto thyroiditis.

The invention provides a plaster formula for treating hashimoto thyroiditis as well as a preparation method and an application method of the plaster formula, and provides a plaster formula for treatment aiming at the defects that at present, symptoms such as thyromegaly, neck fullness and tension, swallowing discomfort and foreign body sensation are not special, and regular observation is mostly adopted for treatment. The traditional Chinese medicine composition comprises the following components in parts by mass: 15-20 parts of ephedra, 30-40 parts of codonopsis pilosula, 40-50 parts of astragalus membranaceus, 15-20 parts of peach kernel, 15-20 parts of raw white paeony root, 3-5 parts of edible tulip, 15-20 parts of radix bupleuri, 20-30 parts of thunberg fritillary bulb, 30-40 parts of raw oyster and 20-30 parts of selfheal. The ointment of the formula is taken externally, the state that no medicine can be used for treating hashimoto thyroiditis at present and observation is dominated can be changed, the ointment has a certain effect on improving thyroid diffuse swelling and neck tension of patients suffering from hashimoto thyroiditis and reducing the antibody level, and a treatment method which is more convenient to accept and easy and convenient to operate is provided for the patients.

The application discloses application of PLEKHO2 and NPM3 autoantibodies in preparation of a kit for detecting hyperactivity of fire due to yin deficiency of Hashimoto's thyroiditis, and the biomarker is at least one of MAP9, IRF9, PLEKHO2, NPM3, DR1, KDM1A, PCGF2, GPCPD1 and IGBP1 related autoantibodies. Among them, the biomarkers for detecting characteristic autoantibodies of the stagnation of liver-Qi of Hashimoto's thyroiditis are MAP9 and IRF9 two related autoantibodies; the biomarkers for detecting characteristic autoantibodies of the hyperactivity of fire due to yin deficiency of Hashimoto's thyroiditis are PLEKHO2 and NPM3 two related autoantibodies; and the biomarkers for detecting characteristic autoantibodies of the deficiency of spleen and kidney yang of Hashimoto's thyroiditis are DR1, KDM1A, PCGF2, GPCPD1 and IGBP1 five related autoantibodies. The serum related autoantibody markers can reflect the syndrome characteristics of Hashimoto's thyroiditis, make the TCM differentiation accurate, and are beneficial to revealing the syndrome essence and molecular connotation of Hashimoto's thyroiditis.